Tonix Pharmaceuticals Holding (TNXP) Consolidated Net Income (2011 - 2026)

Tonix Pharmaceuticals Holding's Consolidated Net Income history runs 16 years deep, the most recent figure standing at -$40.3 million for Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 155.66% year-over-year to -$40.3 million in Q1 2026; TTM through Mar 2026 was -$147.4 million, a 9.88% decrease from a year earlier, with the FY2025 full-year figure at -$127.7 million, up 36.02% from the prior year.
• Consolidated Net Income climbed to -$40.3 million in Q1 2026 per TNXP's latest filing, from -$46.8 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$15.8 million in Q1 2025 and bottomed at -$78.9 million in Q2 2024.
• The 5-year median for Consolidated Net Income is -$29.1 million (2022), against an average of -$31.4 million.
• Across the five-year window, Consolidated Net Income slumped 170.68% in 2024 and surged 64.08% in 2025, its largest moves.
• Year by year, Consolidated Net Income stood at -$31.8 million in 2022, then rose by 15.79% to -$26.8 million in 2023, then grew by 15.88% to -$22.5 million in 2024, then slumped by 107.65% to -$46.8 million in 2025, then advanced by 13.86% to -$40.3 million in 2026.
• Per Business Quant, the three latest TNXP Consolidated Net Income figures stand at -$40.3 million (Q1 2026), -$46.8 million (Q4 2025), and -$31.9 million (Q3 2025).